Adenosine-Cancer Pathway

Targeting the adenosine-cancer pathway with a dual approach.

A significant body of scientific data indicates that targeting the adenosine-cancer pathway – either by using an antagonist to block adenosine from binding to A2A receptors to restore their activity or an antibody to target and block CD73, thereby inhibiting adenosine production – can promote anti-tumor immune responses, leading to tumor regression.

Preclinical studies have shown that blocking both A2A receptors and CD73 may have a synergistic effect in unleashing cancer-killing properties.

For more information on the adenosine-cancer pathway, please see our Annual Report available in the SEC Filings section of the website.

Our Science

We are developing oncology medicines with differentiated mechanisms of action directed at precisely-defined molecular targets

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer